Clinical trials: Mask
Geographic Atrophy, Age Related Macular Degeneration
Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
The purpose of this study is to assess the Safety and Efficacy of IONIS-FB-Lrx for up to 120 patients with Geographic Atrophy secondary to Age Related Macular Degeneration
- Trial name
- NCT03446144
- Testing
- IONIS-FB-Lrx
- Where
- 37 sites in United States, Australia and 1 more
- Sponsor
- Ionis Pharmaceuticals, Inc.
Exudative Age-Related Macular Degeneration
LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration
The purpose of this study is to evaluate the efficacy of 84 successive days of topically administered LHA510 compared to vehicle in reducing the number of patients requiring intravitreal (IVT) anti-vascular endothelial growth…
- Trial name
- NCT02355028
- Testing
- LHA510 ophthalmic suspension, LHA510 vehicle, Ranibizumab ophthalmic solution
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Alcon, a Novartis Company
Macular Degeneration
Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
Prospective, multi-center 2-stage study. Stage 1 (Phase I) is open-label with all patients treated with the NT-503-3 ECT implant. Stage 1 (Phase I) patients will undergo explantation at year 2.
- Trial name
- NCT02228304
- Testing
- NT-503-3 ECT implantation, Eylea® injected intravitreally administered every 8 weeks
- Where
- 38 sites in United States, Israel
- Volunteers
- 42 people
- Sponsor
- Neurotech Pharmaceuticals
Dry Eye Disease (DED)
A Study Evaluating the Efficacy and Safety of RCI001 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye
The objective of this study is to evaluate the safety and efficacy of 0.25% RCI001 Ophthalmic Solution twice a day (BID) and four times a day (QID) compared to placebo (vehicle) in the treatment of the signs and symptoms of dry…
- Trial name
- NCT07068958
- Testing
- 0.25% RCI001 Ophthalmic Solution
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- ORA, Inc.
Dry Eye Disease
A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.
Primary objective To evaluate the efficacy of 5 μg/mL and 10 μg/mL concentrations of the new formulation of rhNGF ophthalmic solution versus vehicle, in order to demonstrate superiority of at least 1 of the concentrations over…
- Trial name
- REDUCO (NCT06244316)
- Testing
- rhNGF 5 μg/mL, rhNGF 10 μg/mL
- Where
- 14 sites in United States, Italy
- Volunteers
- 317 people
- Sponsor
- Dompé Farmaceutici S.p.A
Healthy
Study to Evaluate Safety, Tolerability and Pharmacokinetics of rhNGF Eye Drops in Healthy Volunteers
The primary objective of this study is to assess the safety and tolerability of single and multiple ascending doses of rhNGF when administered as eye drops in healthy subjects.
- Trial name
- NGF0112 (NCT01744704)
- Testing
- rhNGF 0.5 µg/mL Sentinel, rhNGF 5 µg/mL Sentinel, rhNGF 20 µg/mL Sentinel
- Where
- 2 sites in Switzerland, United Kingdom
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Dompé Farmaceutici S.p.A
Cataract
A Bioequivalence Study of Tobradex AF
The purpose of the study is to determine the amount of study medication that moves from the front of the eye into the fluid at the front of the inside of the eye.
- Trial name
- NCT00362895
- Testing
- Tobramycin 0.3% / Dexamethasone 0.033% ophthalmic suspension, Tobramycin 0.3% / Dexamethasone 0.1% ophthalmic suspension (TOBRADEX)
- Where
- United States
- Volunteers
- 995 people
- Sponsor
- Alcon Research
Keratoconjunctivitis Sicca
A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)
The purpose of this study is to evaluate whether SkQ1 ophthalmic solutions are safe and effective compared to placebo for the treatment of the signs and symptoms of dry eye syndrome.
- Trial name
- NCT02121301
- Testing
- Low Dose 0.155µg/mL SkQ1 ophthalmic solution, High Dose 1.55µg/mL SkQ1 ophthalmic solution
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Mitotech, SA
Geographic Atrophy
A Study in Adults With Geographic Atrophy
The purpose of this clinical research study is to look at how safe STL303 is and whether it works when given to people with Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD).
- Trial name
- NCT07606365
- Testing
- STL303
- Where
- 56 sites in United States, Argentina and 5 more
- Volunteers
- 300 people
- Sponsor
- Sitala Bio LTD
Dry Eye Disease (DED)
Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)
This trial will evaluate the efficacy, safety, and tolerability of NOV03 ophthalmic solution in comparison to a saline control for the treatment of the signs and symptoms of Dry Eye Disease (DED) associated with Meibomian Gland…
- Trial name
- NCT04139798
- Testing
- NOV03
- Where
- 29 sites in United States
- Volunteers
- 599 people
- Sponsor
- Bausch & Lomb Incorporated
Inflammation, Cataract
Study of Dexycu in Treating Intraocular Inflammation
This is a phase III, prospective, randomised, double-masked, placebo-controlled, parallel-design, multicenter study of the efficacy, safety and pharmacokinetics of 9% dexamethasone intraocular injection for the treatment of…
- Trial name
- NCT06429306
- Testing
- Dexycu
- Where
- China
- Volunteers
- 285 people
- Sponsor
- Ocumension Therapeutics (Shanghai) Co., Ltd
Obstructive Sleep Apnea
Performance of the Salt Lake Mask System
Assessment of the performance of the Salt Lake mask system acting as a patient interface in the provision of PAP therapy. This study will assess the suitability of this mask system in its current form for use.
- Trial name
- NCT01395693
- Testing
- Salt Lake mask system
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- ResMed
Geographic Atrophy of the Macula
A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD
Age-related macular degeneration (AMD) affects millions of elderly patients. When advanced, there is Geographic Atrophy (GA) in the retina.
- Trial name
- eDREAM (NCT06659549)
- Testing
- GAL-101
- Where
- 24 sites in United States, Armenia and 6 more
- Volunteers
- 110 people
- Sponsor
- Galimedix Therapeutics Inc
Glaucoma, Ocular Hypertension
AR-12286 Fixed Dose Combination to Lower Elevated Intraocular Pressure
This is a double-masked, randomized, controlled study assessing the safety and ocular hypotensive efficacy of two AR 12286/travoprost fixed-dose combination products compared to Travatan® Z in patients with elevated intraocular…
- Trial name
- NCT01474135
- Testing
- 0.25% AR-12286 / 0.004% travoprost, 0.5% AR-12286, 0.004% travoprost, 0.004% Travoprost
- Where
- 9 sites in United States
- Volunteers
- 93 people
- Sponsor
- Aerie Pharmaceuticals
Thyroid Eye Disease
A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Inactive Thyroid Eye Disease
This is a multicenter, randomized, double-masked, placebo-controlled Phase 3 study to evaluate the efficacy, safety, immunogenicity, and population pharmacokinetic (PopPK) characteristics of KHN939 in Chinese patients with…
- Trial name
- Halo-2 (NCT07720648)
- Testing
- KHN939
- Where
- China
- Volunteers
- 117 people
- Sponsor
- Beijing Kanghong Biological Medicine Co., Ltd.
Neovascular Age-related Macular Degeneration
Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration
This study will evaluate and compare two individualized ranibizumab treatment regimens in patients with neovascular (wet) AMD aiming to achieve and to maintain a maximum visual function benefit, while aiming to avoid unnecessary…
- Trial name
- OCTAVE (NCT01780935)
- Testing
- Ranibizumab
- Where
- 92 sites in Argentina, Austria and 22 more
- Volunteers
- 671 people
- Sponsor
- Novartis Pharmaceuticals
Vitreomacular Adhesion
Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial.
The objective of this trial is to evaluate the safety and efficacy of intravitreal microplasmin 125µg dose in subjects wiht focal vitreomacular adhesion.
- Trial name
- NCT00781859
- Testing
- 125 µg Ocriplasmin
- Where
- 41 sites in United States
- Volunteers
- 326 people
- Sponsor
- ThromboGenics
Autosomal Dominant Polycystic Kidney Disease
Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD
To establish pharmacokinetics (PK), pharmacodynamics (PD), and adverse event (AE) profile of tolvaptan administered as the modified-release (MR) formulation in ADPKD subjects. The goals of this trial are two-fold: 1.
- Trial name
- NCT01210560
- Testing
- Tolvaptan MR, Tolvaptan IR
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Diabetic Retinopathy
HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia
This is a study in people with a type of diabetic eye disease called diabetic retinopathy with diabetic macular ischemia. People who have had laser treatment for their diabetic retinopathy can participate in the study.
- Trial name
- HORNBILL (NCT04424290)
- Testing
- BI 764524
- Where
- 19 sites in United States, United Kingdom
- Volunteers
- 45 people
- Sponsor
- Boehringer Ingelheim
Skin Condition, Skin Hydration
Efficacy Test of a Moisturizing and Anti-aging Facial Mask
The objective of this study is to evaluate the effect of Moisturizing facial mask and Anti-aging facial mask on human skin condition improvement.
- Conditions
- Skin Condition, Skin Hydration, Anti Skin Aging
- Trial name
- NCT07622160
- Testing
- Hydrating Repairing Mask, Anti-aging Rejuvenating Mask
- Where
- Taiwan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- TCI Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.